The small molecule CFTR modulators market targets cystic fibrosis treatment, driven by innovative therapies, rising prevalence ...

Cystic fibrosis (CF) is a rare autosomal recessive disorder that affects numerous systems of the body. It is a complicated ...

Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

At 7 years old, Morgan Barrett was diagnosed with cystic fibrosis. Prior to her diagnosis, she struggled to gain weight ...

Cystic Fibrosis is a rare autosomal recessive disease that causes sticky mucus to build up in the lungs, affecting numerous ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® ...

North Carolina man created a foundation to help other patients navigate expenses of an unexpectedly longer life ...

Alphabet Inc.’s Google DeepMind today introduced AlphaGenome, a new artificial intelligence tool that can comprehensively ...

VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.

AlphaGenome scores mutation effects across coding and non-coding DNA, bringing gene insights to the base-pair level.

Ben is running 12 marathons in 12 months to raise awareness for cystic fibrosis, a condition he's battled since childhood.